Roivant Sciences [ROIV] vs Moderna [MRNA] Detailed Stock Comparison
Roivant Sciences
NASDAQ
Loading...
Moderna
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Roivant Sciences wins in 11 metrics, Moderna wins in 7 metrics, with 0 ties. Roivant Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Roivant Sciences | Moderna | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 1.95 | 24.97 | Roivant Sciences |
| Price-to-Book Ratio | 1.76 | 1.16 | Moderna |
| Debt-to-Equity Ratio | 1.93 | 7.88 | Roivant Sciences |
| PEG Ratio | -0.01 | -3.22 | Moderna |
| EV/EBITDA | -3.29 | -2.13 | Roivant Sciences |
| Profit Margin (TTM) | 96.86% | -94.31% | Roivant Sciences |
| Operating Margin (TTM) | -13,130.05% | -638.73% | Moderna |
| Return on Equity | -3.32% | -27.50% | Roivant Sciences |
| Return on Assets (TTM) | -3.16% | -14.77% | Roivant Sciences |
| Free Cash Flow (TTM) | $-844.05M | $-4.06B | Roivant Sciences |
| 1-Year Return | 5.90% | -67.73% | Roivant Sciences |
| Price-to-Sales Ratio (TTM) | 348.30 | 3.54 | Moderna |
| Enterprise Value | $3.77B | $6.51B | Moderna |
| EV/Revenue Ratio | 162.21 | 2.12 | Moderna |
| Gross Profit Margin (TTM) | 92.90% | 13.14% | Roivant Sciences |
| Revenue per Share (TTM) | $0 | $8 | Moderna |
| Earnings per Share (Diluted) | $-1.09 | $-7.51 | Roivant Sciences |
| Beta (Stock Volatility) | 1.15 | 1.83 | Roivant Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Roivant Sciences vs Moderna Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Roivant Sciences | 0.85% | 3.13% | 4.31% | 10.13% | 10.96% | -1.90% |
| Moderna | 4.98% | 7.27% | -11.27% | 18.48% | -21.62% | -33.29% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Roivant Sciences | 5.90% | 220.27% | 19.46% | 19.46% | 19.46% | 19.46% |
| Moderna | -67.73% | -80.82% | -57.83% | 50.65% | 50.65% | 50.65% |
Performance & Financial Health Analysis: Roivant Sciences vs Moderna
| Metric | ROIV | MRNA |
|---|---|---|
| Market Information | ||
| Market Cap | $8.09B | $10.90B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 5,274,610 | 8,365,030 |
| 90 Day Avg. Volume | 5,127,443 | 8,814,440 |
| Last Close | $11.85 | $28.02 |
| 52 Week Range | $8.73 - $13.06 | $23.15 - $91.99 |
| % from 52W High | -9.23% | -69.54% |
| All-Time High | $16.76 (Dec 20, 2021) | $497.49 (Aug 09, 2021) |
| % from All-Time High | -29.30% | -94.37% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.73% | -0.41% |
| Quarterly Earnings Growth | -0.96% | -0.38% |
| Financial Health | ||
| Profit Margin (TTM) | 0.97% | -0.94% |
| Operating Margin (TTM) | -131.30% | -6.39% |
| Return on Equity (TTM) | -0.03% | -0.28% |
| Debt to Equity (MRQ) | 1.93 | 7.88 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.74 | $24.16 |
| Cash per Share (MRQ) | $7.19 | $13.19 |
| Operating Cash Flow (TTM) | $-223,083,000 | $-2,696,999,936 |
| Levered Free Cash Flow (TTM) | $-2,765,250,200 | $-2,864,375,040 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Roivant Sciences vs Moderna
| Metric | ROIV | MRNA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 1.95 | 24.97 |
| Forward P/E | -9.96 | -3.22 |
| PEG Ratio | -0.01 | -3.22 |
| Price to Sales (TTM) | 348.30 | 3.54 |
| Price to Book (MRQ) | 1.76 | 1.16 |
| Market Capitalization | ||
| Market Capitalization | $8.09B | $10.90B |
| Enterprise Value | $3.77B | $6.51B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 162.21 | 2.12 |
| Enterprise to EBITDA | -3.29 | -2.13 |
| Risk & Other Metrics | ||
| Beta | 1.15 | 1.83 |
| Book Value per Share (MRQ) | $6.74 | $24.16 |
Financial Statements Comparison: Roivant Sciences vs Moderna
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ROIV | MRNA |
|---|---|---|
| Revenue/Sales | $2.17M | $107.00M |
| Cost of Goods Sold | $154,000 | $90.00M |
| Gross Profit | $2.02M | $17.00M |
| Research & Development | $152.92M | $856.00M |
| Operating Income (EBIT) | $-284.92M | $-1.05B |
| EBITDA | $-264.70M | $-917.00M |
| Pre-Tax Income | $-269.26M | $-964.00M |
| Income Tax | $4.65M | $7.00M |
| Net Income (Profit) | $-273.91M | $-971.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ROIV | MRNA |
|---|---|---|
| Cash & Equivalents | $2.72B | $1.62B |
| Total Current Assets | $5.00B | $6.77B |
| Total Current Liabilities | $149.41M | $1.60B |
| Long-Term Debt | $90.33M | $702.00M |
| Total Shareholders Equity | $5.19B | $10.07B |
| Retained Earnings | $116.06M | $9.07B |
| Property, Plant & Equipment | $101.08M | $1.25B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ROIV | MRNA |
|---|---|---|
| Operating Cash Flow | $-110.68M | $-691.00M |
| Capital Expenditures | $-811,000 | $-117.00M |
| Free Cash Flow | $-173.38M | $-1.16B |
| Debt Repayment | $0 | N/A |
| Common Stock Repurchase | $-295.45M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ROIV | MRNA |
|---|---|---|
| Shares Short | 38.31M | 63.02M |
| Short Ratio | 6.62 | 6.87 |
| Short % of Float | 0.08% | 0.22% |
| Average Daily Volume (10 Day) | 5,274,610 | 8,365,030 |
| Average Daily Volume (90 Day) | 5,127,443 | 8,814,440 |
| Shares Outstanding | 695.94M | 386.00M |
| Float Shares | 400.09M | 363.31M |
| % Held by Insiders | 0.26% | 0.07% |
| % Held by Institutions | 0.77% | 0.75% |
Dividend Analysis & Yield Comparison: Roivant Sciences vs Moderna
| Metric | ROIV | MRNA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |